Perspective Therapeutics (NASDAQ:CATX) Given Outperform Rating at Wedbush

Perspective Therapeutics (NASDAQ:CATX)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a note issued to investors on Friday,Benzinga reports. They presently have a $11.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 170.27% from the company’s previous close.

A number of other equities analysts have also weighed in on CATX. B. Riley lowered their target price on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Monday, November 24th. They set a “buy” rating and a $12.00 target price for the company. BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a report on Tuesday, January 13th. UBS Group dropped their price objective on Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Perspective Therapeutics in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $11.17.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded down $0.19 during midday trading on Friday, reaching $4.07. The stock had a trading volume of 2,515,574 shares, compared to its average volume of 5,209,135. The business has a fifty day moving average price of $2.61. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.16. The company has a market cap of $302.56 million, a P/E ratio of -4.52 and a beta of 1.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Taylor & Morgan Wealth Management LLC boosted its holdings in Perspective Therapeutics by 6.6% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock valued at $267,000 after purchasing an additional 6,000 shares during the period. R Squared Ltd bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $44,000. Auctus Advisors LLC purchased a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $87,000. Trueblood Wealth Management LLC lifted its position in Perspective Therapeutics by 72.4% in the 4th quarter. Trueblood Wealth Management LLC now owns 119,061 shares of the company’s stock worth $327,000 after buying an additional 50,000 shares during the last quarter. Finally, UBS Group AG boosted its stake in Perspective Therapeutics by 44.5% in the fourth quarter. UBS Group AG now owns 926,331 shares of the company’s stock worth $2,547,000 after buying an additional 285,188 shares in the last quarter. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.